Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor (CAR) modified T cells have shown early promise in hematological malignancies. However, in solid malignancies CAR T cells must overcome a distinct immunosuppressive microenvironment which may compromise their capacity to mediate antitumor activity.
No takes yet. Share an insight, caveat, or question.
Beatty et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: